Saint Luke's Newsroom

Trial findings shared at HFSA’s Annual Scientific Meeting Late-Breaking Clinical Trial Session

Nearly 4,000 runners gathered to compete in the 2019 Plaza 10K to benefit Saint Luke's Home Care and Hospice.

DEFINE-HF was not only the first multi-center randomized placebo-controlled clinical trial that Saint Luke’s developed, coordinated, and implemented in its entirety, but the first significant effort to look at what effect dapagliflozin, a drug initially created for the treatment of diabetes, was going to have in patients who also have heart failure.  

Saint Luke’s cardiologist James O’Keefe, MD, co-authors new study published in Mayo Clinic Proceedings.

Celebrate Life's scheduled events, and activities will focus on starting the conversation with each other about suicide, reducing the stigma of mental illness, hearing testimonials, and providing some training for the community on how to respond to people in need.

The Saint Luke’s Mid America Heart Institute is joining the Cardiothoracic Surgical Trials Network (CTSN) to partner in research with the top surgical centers in the U.S.

In February 1989, Saint Luke’s North Hospital opened its doors. Over the last 30 years, we have continued to grow to meet the changing needs of the Northland.

Two of the Kansas City area’s most respected names in health-sciences education have announced their intent to join forces under an affiliation agreement being signed by Rockhurst University and Saint Luke’s Hospital of Kansas City whereby the Saint Luke’s College of Health Sciences would become part of the University.

The Foundation Fellow Award recognizes individuals who have given time, expertise, and charitable support to advance research, education, and medical programs at Saint Luke’s.